NDAORALSUSPENSION
Approved
Mar 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
7
Data completeness
5/8 — Partial
ARBLI (losartan potassium) by Merck & Co. is [formed from angiotensin i in a reaction catalyzed by angiotensin converting enzyme (ace, kininase ii)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. First approved in 2025.
Drug data last refreshed 13h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARBLI (losartan potassium) is an oral angiotensin II receptor antagonist approved in March 2025 as a suspension formulation for hypertension management. It selectively blocks AT1 receptors to inhibit vasoconstriction and aldosterone secretion, reducing blood pressure through the renin-angiotensin system. The formulation represents a new delivery option for an established mechanism in a large, competitive therapeutic class.
Growth15.0 years to LOE
Early-stage growth trajectory with formulation differentiation; brand team focus on market penetration and adoption communication in competitive hypertension space.
Mechanism of Action
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions
Started Feb 2018
66 enrolled
Healthy
An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)
Started May 2017
15 enrolled
Eosinophilic Esophagitis
Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension
Started Aug 2004
287 enrolled
Essential Hypertension
Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions
Started Mar 2004
80 enrolled
Healthy
A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin
Started Feb 2004
60 enrolled
HypertensionInsulin ResistanceMetabolic Syndrome
Worked on ARBLI at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.